Clinical Trial Update: FCN-338 in Combination With Azacitidine or Chemotherapy in Myeloid Neoplasms [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating FCN-338 in combination with Azacitidine or chemotherapy for myeloid neoplasms. The study is sponsored by Shanghai Fosun…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloid Neoplasms

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• FCN-338

Snippet

Sponsor: Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Conditions: Safety, Antitumor Activity | Phase 2 | Status: ACTIVE_NOT_RECRUITING